During the past 25 years, prospective clinical trials have established that bladder preservation therapy for select patients with muscle-invasive bladder cancer is a safe and effective alternative to an immediate cystectomy.
Cisplatin-based chemoradiation is the most well-studied and accepted component of trimodality therapy; however, other systemic agents have recently been shown effective in combination with radiation therapy, increasing the range of options to allow for better personalization of care. In this review, the most recent advances in the field of bladder-preserving trimodality therapy are presented, and future directions for improving the outcomes are outlined.
Written by:
Mitin T, Shipley WU, Efstathiou JA, Heney NM, Kaufman DS, Lee RJ, Zietman AL. Are you the author?
Harvard Medical School, Massachusetts General Hospital, Department of Radiation Oncology, Boston, MA, 02114, USA.
Reference: Curr Urol Rep. 2013 Jan 23. Epub ahead of print.
doi: 10.1007/s11934-012-0301-x
PubMed Abstract
PMID: 23341373
UroToday.com Bladder Cancer Section
